Core Insights - NeuroBo Pharmaceuticals is advancing the clinical development of DA-1726, a dual agonist for GLP-1 and glucagon receptors, aimed at treating obesity, with top-line data expected in Q3 2024 for Part 1 and Q1 2025 for Part 2 of the Phase 1 trial [1][9] - Recent financing of up to $70 million will support ongoing clinical trials, including a planned Part 3 to assess total weight loss and dietary changes, with interim data expected in mid-2026 [1][10] Company Overview - NeuroBo Pharmaceuticals is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, currently developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [13] - DA-1726 is designed to be administered once weekly subcutaneously and has shown superior weight loss in pre-clinical models compared to existing treatments like semaglutide and tirzepatide [12][13] Clinical Trial Details - The Phase 1 trial consists of two parts: Part 1 (Single Ascending Dose) and Part 2 (Multiple Ascending Dose), with approximately 45 participants in Part 1 and 36 in Part 2, randomized to receive either DA-1726 or placebo [17] - Primary endpoints focus on safety and tolerability, while secondary endpoints will assess pharmacokinetics and exploratory endpoints will evaluate metabolic and cardiac parameters [2][17]
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity